Introduction
This blog post will do a summary about Nordic Nanovector, and its stock. As always, do your own due diligence and refer directly to sources before making any investment decisions!
- Background about the company and its lead product
- Recent developments and possible short term triggers.
- Technical analysis suggesting an end to four years of bear market
- Radiopharmaceuticals and theranostics gaining main stream acceptance
- Recent M&A activity in the commercial space
Background about the company and its lead product
Nordic Nanovector IR: https://www.nordicnanovector.com/investors-and-media/reports-and-presentations/interim-reports
Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?term=betalutin
Betalutin Fast Track Designation: https://nanoinvestors.wordpress.com/betalutin-fda-fast-track-status/
Recent developments and possible short term triggers.
- New CEO Peter L Braun joining Nordic Nanovector at the perfect time to play a role in commercialization efforts. On his Linkedin profile, he among others list experience from Roche with the launch of Mabthera / Rituximab.
https://nanoinvestors.wordpress.com/2021/03/20/peter-l-braun-joins-nordic-nanovector-as-ceo/
- Nordic Nanovector Q4 2020 presentation: PARADIGME recruitment accelerated, aims for Betalutin filing in 2021
https://nanoinvestors.wordpress.com/2021/02/18/nordic-nanovector-q4-2020-presentation-paradigme-recruitment-accelerated-aims-for-betalutin-filing-in-2021/
- Successfull private placement and prospectus for repair offering of company stock
https://vp239.alertir.com/en/pressreleases/nordic-nanovector-asa%3A-prospectus-approved-1899092 - Most important near term trigger would be for the company to further reinforce that recruitment into PARADIGME is solidly back ontrack.
Technical analysis suggesting an end to four years of bear market
- Enormous trading volume
- Golden cross 50 / 200 SMA
- Stock retracing and making positive notes on breaking out from short term triangle formation.
Radiopharmaceuticals and theranostics gaining main stream acceptance
Recent M&A and fund raise activity in the commercial space
- Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
- Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ
- EvaluateVantage: Novartis goes nuclear, again
Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion
The Bacon Portfolio 